Cell No. : Cell Name
RCB1468 : Btk^(-) DT40
update : 2024/11/13
|
| Comment | Btk deficient DT40 cells |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Kurosaki, Tomohiro
|
| Originator |
Kurosaki, Tomohiro
|
| Year of deposit |
1998
|
| Another name |
B7-10
|
| Original cell |
DT40
|
| Animal |
_avian
< Birds
|
| Tissue |
B cell
|
| Classification |
mutant
|
| Recombinant |
recombinant
|
|
Lifespan |
infinite
|
| Morphology |
lymphocyte-like
|
| Cellosaurus(Expasy) |
CVCL_1T45
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Suspension cells
|
| Culture method |
|
浮遊細胞の培養に関する一般的な注意(Japanese)
|
| Culture medium |
|
RPMI1640 (4mM Glutamine) + 10% FBS + 1% Chicken serum + 50μM 2-Mercaptoethanol
|
| Antibiotics |
|
Free
|
|
Passage method |
|
dilution
|
Culture information
|
Passage cell No |
|
1.5-2 x 10 5 cells/ml
|
| Passage ratio |
|
1 : 20 split
|
| SC frequency |
|
Subculture : every 2 days
|
| Temperature |
|
39.5
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
90% FBS + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| Animal PCR |
|
OK
|
| Others |
|
Freezing : 1.0-1.5x10 7 cells/ml/vial. Thawing : 1ml of cells into 20ml media. It is unnecessary to remove DMSO. Pass the next day.
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
1
|
| User's Publication |
3
|
| User's Publication |
|
14386
Hing ZA, Mantel R, Beckwith KA, Guinn D, Williams E, Smith LL, Williams K, Johnson AJ, Lehman AM, Byrd JC, Woyach JA, Lapalombella R.
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia
Blood
2015
125(20):3128-32
PubMed ID: 25838351
DOI: 10.1182/blood-2015-01-621391
|
|
18613
de Gorter DJ, Vos JC, Pals ST, Spaargaren M.
The B cell antigen receptor controls AP-1 and NFAT activity through Ras-mediated activation of Ral
J Immunol
2007
178(3):1405-14
PubMed ID: 17237388
DOI: 10.4049/jimmunol.178.3.1405
|
|
17351
Blois JT, Mataraza JM, Mecklenbraüker I, Tarakhovsky A, Chiles TC.
B cell receptor-induced cAMP-response element-binding protein activation in B lymphocytes requires novel protein kinase Cdelta
J Biol Chem
2004
279(29):30123-32
PubMed ID: 15138267
DOI: 10.1074/jbc.M402793200
|
Back
Top
CELL BANK Website